DK0862562T3 - Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler - Google Patents
Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midlerInfo
- Publication number
- DK0862562T3 DK0862562T3 DK96930365T DK96930365T DK0862562T3 DK 0862562 T3 DK0862562 T3 DK 0862562T3 DK 96930365 T DK96930365 T DK 96930365T DK 96930365 T DK96930365 T DK 96930365T DK 0862562 T3 DK0862562 T3 DK 0862562T3
- Authority
- DK
- Denmark
- Prior art keywords
- stands
- preparation
- optionally substituted
- reducing agents
- lipid level
- Prior art date
Links
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003638 chemical reducing agent Substances 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23545795 | 1995-09-13 | ||
PCT/JP1996/002596 WO1997010224A1 (en) | 1995-09-13 | 1996-09-12 | Benzoxazepine compounds, their production and use as lipid lowering agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0862562T3 true DK0862562T3 (da) | 2001-09-24 |
Family
ID=16986391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96930365T DK0862562T3 (da) | 1995-09-13 | 1996-09-12 | Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler |
Country Status (8)
Country | Link |
---|---|
US (5) | US6110909A (da) |
EP (1) | EP1097928B1 (da) |
AT (2) | ATE401315T1 (da) |
CA (1) | CA2231052C (da) |
DE (2) | DE69637603D1 (da) |
DK (1) | DK0862562T3 (da) |
ES (1) | ES2158344T3 (da) |
PT (1) | PT862562E (da) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2231052C (en) * | 1995-09-13 | 2007-11-13 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
US6537987B1 (en) * | 1996-06-20 | 2003-03-25 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
WO2002038180A1 (fr) * | 2000-11-09 | 2002-05-16 | Takeda Chemical Industries, Ltd. | Agent haute densite faisant monter le taux de lipoproteine-cholesterol |
US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20030224047A1 (en) * | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
BR0207297A (pt) * | 2001-02-15 | 2005-04-19 | King Pharmaceuticals Inc | Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo |
US20020193440A1 (en) * | 2001-02-20 | 2002-12-19 | Ritter Steven C. | Liothyronine sodium and levothyroxine sodium combination |
WO2003002147A1 (fr) * | 2001-06-28 | 2003-01-09 | Takeda Chemical Industries, Ltd. | Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes |
US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
US20030199587A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique Cmax properties |
US20030199586A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Unique levothyroxine aqueous materials |
US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
US20030190359A1 (en) * | 2001-10-29 | 2003-10-09 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
TW200510356A (en) * | 2003-08-01 | 2005-03-16 | Takeda Chemical Industries Ltd | Benzoxaepine compounds |
MXPA06014152A (es) * | 2004-06-11 | 2007-01-29 | Takeda Pharmaceutical | Metodo de amidacion novedoso, altamente selectivo. |
CN101277949A (zh) * | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
US20090088416A1 (en) * | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
GB202214609D0 (en) | 2022-10-04 | 2022-11-16 | Francis Crick Institute Ltd | Methods of treatment of intestinal infections |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0567026A (ja) | 1991-09-10 | 1993-03-19 | Shikoku Nippon Denki Software Kk | 周辺装置制御装置 |
US5726306A (en) * | 1992-04-20 | 1998-03-10 | Takeda Chemical Industries, Ltd. | 4,1-benzoxazepin derivatives and their use |
EP0567026B1 (en) * | 1992-04-20 | 2003-03-26 | Takeda Chemical Industries, Ltd. | 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides |
JP3128972B2 (ja) | 1992-07-24 | 2001-01-29 | ソニー株式会社 | 電子モジュールの製造方法 |
JPH075607A (ja) | 1993-06-15 | 1995-01-10 | Konica Corp | ハロゲン化銀写真感光材料 |
JPH0710725A (ja) | 1993-06-28 | 1995-01-13 | Mitsui Toatsu Chem Inc | シャンプー組成物 |
AU678503B2 (en) * | 1993-09-24 | 1997-05-29 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds and their use as squalene synthetase inhibitors |
AU1589895A (en) * | 1994-02-09 | 1995-08-29 | Takeda Chemical Industries Ltd. | Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors |
TW401301B (en) * | 1994-10-07 | 2000-08-11 | Takeda Chemical Industries Ltd | Antihypertriglyceridemic composition |
EP0710725A1 (en) * | 1994-11-01 | 1996-05-08 | Takeda Chemical Industries, Ltd. | Production of optically active compounds |
CA2231052C (en) * | 1995-09-13 | 2007-11-13 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
US6537987B1 (en) * | 1996-06-20 | 2003-03-25 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
US5886979A (en) * | 1996-10-21 | 1999-03-23 | Fujitsu Limitd | Information recording medium and method for recording and reproducing information to a medium to prevent unauthorized copying |
WO2002038180A1 (fr) * | 2000-11-09 | 2002-05-16 | Takeda Chemical Industries, Ltd. | Agent haute densite faisant monter le taux de lipoproteine-cholesterol |
WO2003002147A1 (fr) * | 2001-06-28 | 2003-01-09 | Takeda Chemical Industries, Ltd. | Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes |
-
1996
- 1996-09-12 CA CA002231052A patent/CA2231052C/en not_active Expired - Fee Related
- 1996-09-12 DE DE69637603T patent/DE69637603D1/de not_active Expired - Lifetime
- 1996-09-12 DE DE69613710T patent/DE69613710T2/de not_active Expired - Lifetime
- 1996-09-12 PT PT96930365T patent/PT862562E/pt unknown
- 1996-09-12 AT AT00126672T patent/ATE401315T1/de not_active IP Right Cessation
- 1996-09-12 AT AT96930365T patent/ATE202774T1/de not_active IP Right Cessation
- 1996-09-12 ES ES96930365T patent/ES2158344T3/es not_active Expired - Lifetime
- 1996-09-12 US US09/043,265 patent/US6110909A/en not_active Expired - Fee Related
- 1996-09-12 DK DK96930365T patent/DK0862562T3/da active
- 1996-09-12 EP EP00126672A patent/EP1097928B1/en not_active Expired - Lifetime
-
2000
- 2000-06-06 US US09/587,947 patent/US6613761B1/en not_active Expired - Fee Related
-
2003
- 2003-06-24 US US10/606,152 patent/US20040072819A1/en not_active Abandoned
-
2006
- 2006-12-12 US US11/638,066 patent/US20070117787A1/en not_active Abandoned
-
2007
- 2007-11-19 US US11/986,280 patent/US20080153801A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2158344T3 (es) | 2001-09-01 |
US20070117787A1 (en) | 2007-05-24 |
DE69613710T2 (de) | 2001-11-08 |
US20080153801A1 (en) | 2008-06-26 |
US20040072819A1 (en) | 2004-04-15 |
EP1097928B1 (en) | 2008-07-16 |
ATE202774T1 (de) | 2001-07-15 |
EP1097928A1 (en) | 2001-05-09 |
PT862562E (pt) | 2001-11-30 |
DE69613710D1 (de) | 2001-08-09 |
CA2231052C (en) | 2007-11-13 |
CA2231052A1 (en) | 1997-03-20 |
DE69637603D1 (de) | 2008-08-28 |
US6110909A (en) | 2000-08-29 |
US6613761B1 (en) | 2003-09-02 |
ATE401315T1 (de) | 2008-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0862562T3 (da) | Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler | |
BE2018C008I2 (da) | ||
CY1113054T1 (el) | Παραγωγα διαμινης | |
AU2002246728A1 (en) | Carboline derivatives | |
GB0124627D0 (en) | Novel compounds | |
AU2002249890A1 (en) | Carboline derivatives | |
PT918776E (pt) | Sintese total de acilfulvenos antitumorais | |
EP0903347A4 (da) | ||
TR200101711T2 (tr) | Antihistaminik spiro bileşikler. | |
DE69810960D1 (de) | 2-phenoxyanilin-derivate | |
EP0721949A4 (da) | ||
HK1046683A1 (en) | Carbamoyl tetrahydropyridine derivatives. | |
WO1996005182A3 (de) | Saccharinderivate | |
FI952420A (fi) | Glukopyranosidibentsotiofeenit | |
AU670675B2 (en) | Morpholine derivative | |
DK1338596T3 (da) | Fremgangsmåde til fremstilling af antibakterielt middel af carbapenemtypen | |
TW364908B (en) | Quinolone- and naphthyridonecarboxylic acid derivatives | |
DE69915688D1 (de) | Benzonaphtyridin-1,8 derivate | |
UA39157C2 (uk) | Спосіб одержання похідних 2-арил-3-метил-4-оксо-3,4-дигідрохіназоліну та похідні 7-азабензонорборнену як проміжні сполуки |